rpid-202508080001380106false00013801062025-08-082025-08-08
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 8, 2025
RAPID MICRO BIOSYSTEMS, INC.
(Exact name of registrant as specified in its charter)
| | | | | | | | |
| Delaware | 001-40592 | 20-8121647 |
(State or other jurisdiction
of incorporation or organization) | (Commission
File Number) | (I.R.S. Employer
Identification No.) |
25 Hartwell Avenue, Lexington, MA | | 02421 |
(Address of principal executive offices) | | (Zip Code) |
978-349-3200
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| | | | | |
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | | | | | | | |
| Title of each class | | Trading
Symbols | | Name of each exchange on which
registered |
| Class A Common Stock, $0.01 par value per share | | RPID | | The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company þ
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
| | | | | |
Item 1.01 | Entry into a Material Definitive Agreement. |
On August 8, 2025 (the “Closing Date”), Rapid Micro Biosystems, Inc. (the "Company") entered into a Loan and Security Agreement (the “LSA”) with the lenders party thereto (the “Lenders”) and Trinity Capital Inc., as administrative agent and collateral agent (the “Agent”).
Under the LSA, the Lenders agreed to extend debt capital to the Company, in the form of a term loan, in tranches totaling an aggregate principal amount of up to $45.0 million available as follows: (a) at closing, an aggregate principal amount of $20.0 million (the “First Tranche”), (b) until January 31, 2027, subject to the achievement of certain commercial and operational milestones, an aggregate principal amount of $10.0 million (the “Second Tranche”), (c) until July 31, 2027, subject to the achievement of certain commercial and operational milestones, an aggregate principal amount of $10.0 million (the “Third Tranche”), and (d) an aggregate principal amount of $5.0 million in Lenders’ sole discretion (the “Fourth Tranche” and collectively with the First Tranche, the Second Tranche and the Third Tranche, the “Tranches”). The obligations of the Lenders to extend such debt capital are subject to certain conditions precedent described in the LSA. The Company is required to pay a commitment fee of 1.0% of the amount drawn, plus related documentation and funding fees, in connection with each drawdown. On (the Closing Date, the Company drew down the First Tranche. The Company’s obligations under the facility may be guaranteed by certain subsidiaries and are secured by a first priority security interest in substantially all assets of the Company and any subsidiaries providing a guarantee.
In connection with the drawdown of any Tranche, the Company is required to issue to the Lenders a warrant to purchase shares of the Company’s Class A common stock (the “Common Stock”). The exercise price (“Exercise Price”) for each warrant shall be equal to the lower of (a) the volume-weighted average price of the Common Stock over the ten days prior to the drawdown, and (b) the closing price of the Common Stock on the day immediately prior to the drawdown. The number of shares of Common Stock for which each warrant is exercisable is equal to 3.0% of the drawn down amount of the applicable Tranche, divided by the Exercise Price. Each warrant shall have a term of ten years from the date of issuance and shall permit cashless exercise, all in accordance with its terms. In connection with the drawdown of the First Tranche, for no additional consideration, the Company issued warrants to purchase up to an aggregate of 179,104 shares of Common Stock, with an Exercise Price of $3.35 per share. Such warrants were issued in a placement transaction exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof and/or Rule 506 of Regulation D promulgated thereunder.
All Tranches will mature on September 1, 2030 (the “Maturity Date”), unless earlier accelerated under the terms of the LSA. At maturity, the Company is required to repay the then-outstanding principal amount, together with any accrued and unpaid interest thereon and any other obligations outstanding under the LSA. In addition, at maturity or early termination of the LSA, including acceleration of the loans, the Company is required to pay the Lenders an additional 4.0% of the amounts drawn down by the Company under the LSA (the "End of Term Payment").
Interest accrues on the Tranches that the Company has drawn down at a floating rate per annum, calculated based on a 360-day year, equal to the greater of (a) the sum of (i) The Wall Street Journal Prime Rate and (ii) 4.0%, and (b) 11.0%. The initial interest rate is 11.5% per annum. For the first 36 months after the Closing Date (the “Interest Only Period”), the Company is required to make only monthly payments of interest in arrears. Following such period, and until the Maturity Date (the “Amortization Period”), the Company is required to make monthly payments of principal and interest in an amount that fully amortizes the outstanding principal balance due over the duration of the Amortization Period. If the Second Tranche is fully drawn down by the Company, the Interest Only Period will be extended by six months. If the Third Tranche is fully drawn down by the Company, the Interest Only Period will be extended by a further six months. In the event of such extensions of the Interest Only Period, the duration of the Amortization Period will decrease by the same amount. In any event, the total term of all Tranches shall not exceed 60 months.
The Company may voluntarily prepay the outstanding loan balance at any time, in whole or in part, subject to the payment of prepayment premiums. If prepayment occurs on or before the first anniversary of the Closing Date, the premium shall equal 3.0% of the principal being repaid. Thereafter, if prepayment occurs on or before the second anniversary of the Closing Date, the premium shall equal 2.0% of the principal being repaid. Thereafter, the premium shall equal 1.0% of the principal being repaid. For the avoidance of doubt, such prepayment premiums are in addition to the End of Term Payment. Additionally, the Company is required to prepay the outstanding loan balance (plus accrued and unpaid interest thereon, any prepayment premiums and any other obligations that are due and payable) upon a sale, divestment or transfer of all or substantially all assets of the Company and its subsidiaries, taken as a whole, or of a material business line of the Company, the acquisition by a person or group of a sufficient number of the Company’s equity securities to elect a majority of the members of the Company’s board of directors, or the acceleration of the loans by the Agent on behalf of the Lenders following an event of default under the LSA.
The LSA contains customary affirmative and negative covenants, including with respect to notice obligations, limitations on new indebtedness, liens, investments and transactions with affiliates of the Company, restrictions on the
payment of dividends, maintenance of collateral and accounts and maintenance of insurance. The LSA does not contain any covenants to maintain a specified level of revenues or cash resources.
The LSA contains customary representations and warranties of the Company, as well as customary events of default, the occurrence of which may accelerate the obligations of the Company, increase the interest rate by a specified default rate and impose other consequences described in the LSA. Such events include among others, failure to make payments when due, breach of covenants, insolvency, a cross-default to other indebtedness, a judgment event of default, the occurrence of a material adverse change to the Company,and delisting of the Company’s securities from Nasdaq.
The foregoing description of the LSA does not purport to be complete and is qualified in its entirety by reference to the full text of the LSA, which will filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2025 and is incorporated herein by reference.
| | | | | |
Item 2.02 | Results of Operations and Financial Condition. |
On August 12, 2025, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its second quarter ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety.
The information furnished under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as otherwise expressly stated in such filing.
| | | | | |
Item 2.03 | Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. |
The information set forth in Item 1.01 above is hereby incorporated by reference into Item 2.03.
| | | | | |
Item 3.02 | Unregistered Sales of Equity Securities. |
The information set forth in Item 1.01 above is hereby incorporated by reference into Item 3.02.
| | | | | |
Item 7.01 | Regulation FD Disclosure. |
On August 12, 2025, the Company issued a press release regarding the LSA, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information furnished under this Item 7.01, including Exhibit 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as otherwise expressly stated in such filing.
| | | | | |
Item 9.01 | Financial Statements and Exhibits. |
(d)Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | |
| RAPID MICRO BIOSYSTEMS, INC. |
| |
| Date: August 12, 2025 | By: | /s/ Sean Wirtjes |
| | Sean Wirtjes |
| | Chief Financial Officer |
Exhibit 99.1
Rapid Micro Biosystems Reports Second Quarter 2025 Financial Results
•Reports second quarter 2025 total revenue of $7.3 million, representing 10% growth compared to the second quarter of 2024.
◦Second quarter 2025 recurring revenue increased 15% compared to the second quarter of 2024.
•Reports second quarter gross margin of 4%, representing a seven-percentage point improvement compared to the second quarter of 2024.
•Enters into five-year, $45 million term loan facility with $20 million funded at close.
•Reaffirms full-year 2025 total revenue guidance of at least $32.0 million.
Lexington, MA, August 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the second quarter ended June 30, 2025.
"Our second quarter results reflect broad-based, consistent execution across the business," said Robert Spignesi, President and CEO. "Total revenue increased 10%, driven by an 18% increase in Service revenue. Product revenue increased by 6%, led by mid-teens growth in consumables. With continued strong customer interest in Growth Direct and meaningful progress across our broader business, we are reiterating our full-year 2025 revenue guidance."
"In addition, this morning we announced a new five-year, $45 million term loan facility, with $20 million funded upfront with highly favorable terms, including no financial or liquidity covenants," continued Spignesi. "This facility significantly strengthens our financial position and reinforces our ability to achieve positive cash flow. Our strategic priorities remain unchanged, and this capital supports our continued focus on delivering significant long-term revenue growth, gross margin expansion and shareholder value."
Second Quarter Financial Results
Total revenue for the second quarter of 2025 increased 10% to $7.3 million compared to $6.6 million in the second quarter of 2024. The Company placed four new Growth Direct® systems and completed the validation of two customer systems compared to five placements and five validations in the second quarter of 2024. Product revenue increased by 6% to $4.8 million, compared to $4.5 million in the second quarter of 2024. Service revenue increased by 18% to $2.5 million, compared to $2.1 million in the second quarter of 2024. Recurring revenue increased by 15% to $4.4 million, compared to $3.8 million in the second quarter of 2024.
Total cost of revenue was $7.0 million in the second quarter of 2025, an increase of 3% compared to $6.8 million in the second quarter of 2024. Gross margin was positive 4%, or positive $0.3 million, compared to negative 3%, or negative $0.2 million in the second quarter of 2024.
Total operating expenses decreased by 6% to $12.4 million in the second quarter of 2025, compared to $13.2 million in the second quarter of 2024. General and administrative expenses increased 4%, research and development expenses decreased by 14%, and sales and marketing expenses decreased by 14%, in each case compared to the second quarter of 2024.
Net loss for the second quarter of 2025 was $11.9 million, compared to $12.6 million in the second quarter of 2024. Net loss per share for the second quarter of 2025 was $0.27, compared to $0.29 in the second quarter of 2024.
Cash, cash equivalents, short-term investments, and restricted cash were approximately $32 million as of June 30, 2025.
2025 Outlook
The Company is reaffirming its full year 2025 total revenue guidance of at least $32.0 million.
Loan Facility
In a separate release issued today, the Company announced that it has entered into a five-year, $45 million term loan facility with Trinity Capital Inc. The Company received $20 million at close through the first tranche and has access to two additional tranches totaling $20 million, subject to the achievement of certain commercial and operational milestones. A fourth tranche of $5 million is available at the lender's discretion.
For additional details regarding this facility, please refer to the related press release at https://investors.rapidmicrobio.com/news-and-events/news-releases.
Webcast Details
The Company will host a conference call before the market opens today, August 12, 2025, at 8:30 a.m. ET to discuss its second quarter 2025 financial results. The live call is accessible on the Company’s website at investors.rapidmicrobio.com and will be archived and available for replay for one year.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered in Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.
Rapid Micro Biosystems intends to use the Investor Relations page of its website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor its website in addition to following press releases, filings with the Securities and Exchange Commission (“SEC”), public conference calls, presentations and webcasts.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the Company’s guidance, including with respect to full year 2025 total revenue and number of Growth Direct placements; the Company's goal of achieving cash flow breakeven; the Company's newly-announced debt facility; the Company’s ability to reduce product costs, and improve manufacturing efficiency and service productivity; and the Company's ability to advance its priorities of accelerating Growth Direct system placements, improving gross margins and innovating new products.
In some cases, you can identify forward-looking statements by terminology such as “outlook,” “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including, but not limited to risks related to, the Company's ability to achieve positive cash flow; the Company's ability to achieve its business objectives; the Company's significant losses since inception; the Company’s ability to meet its publicly announced guidance and other expectations about its business and operations; the impact of the Company's existing and any future indebtedness on its ability to operate its business; the Company’s ability to access any future tranches under its debt facility and to comply with all of its obligations thereunder, the Company’s limited experience in marketing and sales and the effectiveness of its sales processes; the Company’s need to develop new products and adapt to technological changes; the Company’s ability to establish and maintain its position as a leading provider of automated microbial quality control testing; the Company’s ability to maintain its manufacturing facility; the Company's ability to improve the gross margins of its products and
services; risks related to third-parties; the Company’s ability to retain key management and other employees; risks related to regulatory and intellectual property matters; risks related to supply chain disruptions and the impact of inflation; risks associated with macroeconomic events and uncertainty, including with respect to tariff and trade policy in the U.S. and abroad, as well as activity in the Company's industry and in the general economy; and the other important factors outlined under the caption “Risk Factors” in the Company’s Quarterly Report on Form 10-Q filed with the SEC, as such factors may be updated from time to time in its other filings with the SEC, which are available on the SEC's website at www.sec.gov and the Investor Relations page of its website at investors.rapidmicrobio.com. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.
Investor Contact
Michael Beaulieu, CFA
Vice President, Investor Relations and Corporate Communications
Media Contact
RAPID MICRO BIOSYSTEMS, INC.
Unaudited Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended June 30, | | Six Months Ended June 30, | | | |
| 2025 | | 2024 | | 2025 | | 2024 | | | | | | | |
| Revenue: | | | | | | | | | | | | | | |
| Product revenue | $ | 4,802 | | | $ | 4,537 | | | $ | 8,903 | | | $ | 8,250 | | | | | | | | |
| Service revenue | 2,460 | | | 2,081 | | | 5,564 | | | 3,979 | | | | | | | | |
| Total revenue | 7,262 | | | 6,618 | | | 14,467 | | | 12,229 | | | | | | | | |
| Costs and operating expenses: | | | | | | | | | | | | | | |
| Cost of product revenue | 5,315 | | | 4,917 | | | 10,344 | | | 10,090 | | | | | | | | |
| Cost of service revenue | 1,672 | | | 1,890 | | | 3,444 | | | 3,851 | | | | | | | | |
| Research and development | 3,230 | | | 3,744 | | | 6,854 | | | 7,586 | | | | | | | | |
| Sales and marketing | 3,114 | | | 3,627 | | | 5,865 | | | 6,908 | | | | | | | | |
| General and administrative | 6,079 | | | 5,818 | | | 11,769 | | | 11,445 | | | | | | | | |
| Total costs and operating expenses | 19,410 | | | 19,996 | | | 38,276 | | | 39,880 | | | | | | | | |
| Loss from operations | (12,148) | | | (13,378) | | | (23,809) | | | (27,651) | | | | | | | | |
| Other income (expense): | | | | | | | | | | | | | | |
| Interest income, net | 351 | | | 838 | | | 817 | | | 1,821 | | | | | | | | |
| Other expense, net | (50) | | | (23) | | | (111) | | | (52) | | | | | | | | |
| Total other income, net | 301 | | | 815 | | | 706 | | | 1,769 | | | | | | | | |
| Loss before income taxes | (11,847) | | | (12,563) | | | (23,103) | | | (25,882) | | | | | | | | |
| Income tax expense | 11 | | | 15 | | | 18 | | | 18 | | | | | | | | |
| Net loss | $ | (11,858) | | | $ | (12,578) | | | (23,121) | | | (25,900) | | | | | | | | |
| Net loss per share — basic and diluted | $ | (0.27) | | | $ | (0.29) | | | $ | (0.52) | | | $ | (0.60) | | | | | | | | |
| Weighted average common shares outstanding — basic and diluted | 44,648,602 | | 43,616,501 | | 44,321,566 | | 43,431,170 | | | | | | | |
RAPID MICRO BIOSYSTEMS, INC.
Unaudited Condensed Consolidated Balance Sheets
(in thousands)
| | | | | | | | | | | |
| June 30,
2025 | | December 31,
2024 |
| Assets | | | |
| Current assets: | | | |
| Cash and cash equivalents | $ | 18,333 | | | $ | 16,911 | |
| Short-term investments | 12,922 | | | 33,821 | |
| Accounts receivable | 6,048 | | | 7,519 | |
| Inventory | 20,560 | | | 20,200 | |
| Prepaid expenses and other current assets | 2,283 | | | 2,466 | |
| Total current assets | 60,146 | | | 80,917 | |
| Property and equipment, net | 10,205 | | | 11,193 | |
| Right-of-use assets, net | 4,640 | | | 5,163 | |
| | | |
| Other long-term assets | 311 | | | 531 | |
| Restricted cash | 284 | | | 365 | |
| Total assets | $ | 75,586 | | | $ | 98,169 | |
| Liabilities and Stockholders’ Equity | | | |
| Current liabilities: | | | |
| Accounts payable | $ | 3,334 | | | $ | 2,535 | |
| Accrued expenses and other current liabilities | 5,678 | | | 7,217 | |
| Deferred revenue | 6,136 | | | 6,599 | |
| Lease liabilities, short-term | 1,255 | | | 1,214 | |
| Total current liabilities | 16,403 | | | 17,565 | |
| | | |
| Lease liabilities, long-term | 4,324 | | | 4,954 | |
| Other long-term liabilities | 314 | | | 298 | |
| Total liabilities | 21,041 | | | 22,817 | |
| Total stockholders’ equity | 54,545 | | | 75,352 | |
| Total liabilities and stockholders’ equity | $ | 75,586 | | | $ | 98,169 | |
RAPID MICRO BIOSYSTEMS, INC.
Unaudited Cash, Cash Equivalents and Investments
(in thousands)
| | | | | | | | | | | |
| June 30,
2025 | | December 31,
2024 |
| Cash and cash equivalents | $ | 18,333 | | | $ | 16,911 | |
| Short-term investments | 12,922 | | | 33,821 | |
| | | |
| Cash, cash equivalents and investments | $ | 31,255 | | | $ | 50,732 | |
Exhibit 99.2
Rapid Micro Biosystems Enters into Five-Year, $45 Million Term Loan Facility with Trinity Capital Inc.
•$20 million drawn down at closing, with access to up to an additional $25 million
•Strengthens Company’s financial position and reinforces ability to achieve positive cash flow
Lexington, Mass., August 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company” or “Rapid Micro”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that it has entered into a five-year, $45 million term loan facility with Trinity Capital Inc. (Nasdaq: TRIN) ("Trinity Capital").
Proceeds from this facility will be used for general corporate purposes, which may include supporting the continued global commercial expansion of the Growth Direct system, and ongoing investments in manufacturing efficiencies, service productivity, and product cost reduction initiatives.
“This facility significantly strengthens our financial position and supports our continued focus on long-term revenue growth, margin expansion and increasing shareholder value,” said Robert Spignesi, President and CEO of Rapid Micro Biosystems. “We are pleased with the highly favorable terms of this facility, which positions us well to build on our meaningful progress across the business.”
The loan facility consists of four tranches, with the first tranche of $20 million drawn upon closing of the agreement. The second and third tranches totaling $20 million are available to be drawn subject to the achievement of certain commercial and operational milestones, and the fourth tranche of $5 million is available at the lender’s discretion. Interest is payable on the outstanding principal amount at a floating rate, initially 11.5% per annum. The loan facility has a five-year term with an interest-only period of 36 months, which is extendable if future tranches are drawn down. The loan facility contains customary representations, warranties, covenants and events of default but does not require the Company to maintain a specified level of revenues or cash resources.
The Growth Direct system is the only fully automated, non-destructive growth-based platform for MQC testing that offers manufacturers faster time to results, improved data integrity and enhanced accuracy.
Armentum Partners acted as the Company’s exclusive financial advisor on this transaction.
To learn more about the Company and the Growth Direct® platform, please visit our website at www.rapidmicrobio.com.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered in Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland,
Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the Company’s newly-announced term loan facility, including the planned use of proceeds therefor and the intended benefits thereof.
In some cases, you can identify forward-looking statements by terminology such as “outlook,” “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including, but not limited to, the impact of the Company's existing and any future indebtedness on its ability to operate its business; the Company’s ability to access any future tranches under its debt facility and to comply with all of its obligations thereunder; the Company’s ability to achieve its goal of attaining positive cashflow; and the other important factors outlined under the caption “Risk Factors” in the Company’s most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on May 9, 2025, as such factors may be updated from time to time in its other filings with the SEC, which are available on the SEC's website at www.sec.gov and the Investor Relations page of its website at investors.rapidmicrobio.com. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.
Rapid Micro Biosystems Investor Contact:
Michael Beaulieu, CFA
Vice President, Investor Relations and Corporate Communications
Rapid Micro Biosystems Media Contact: